Compare · REGN vs XBIT

REGN vs XBIT

Side-by-side comparison of Regeneron Pharmaceuticals Inc. (REGN) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both REGN and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • REGN is the larger of the two at $95.24B, about 1805.8x XBIT ($52.7M).
  • REGN has been more active in the news (26 items in the past 4 weeks vs 7 for XBIT).
  • REGN has more recent analyst coverage (25 ratings vs 0 for XBIT).
MetricREGNXBIT
Company
Regeneron Pharmaceuticals Inc.
XBiotech Inc.
Price
-
-
Market cap
$95.24B
$52.7M
1M return
+12.42%
-
1Y return
+25.03%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
1991
2015
News (4w)
26
7
Recent ratings
25
0
REGN

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

XBIT

XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Latest REGN

Latest XBIT